I am an attending physicist with expertise and board certification in physics of nuclear medicine and radiation therapy, and I am involved in clinical work, teaching, and research.
My research is in applying physical and numerical methods for extracting information about biological structure, function, and the effects of radiation. Recent examples include investigations of correlations between the distribution of radiotracer uptake and histopathology findings in biopsy specimens extracted under PET/CT guidance, correlations of radiotracer uptake with genomic mutations in tumors, and evaluation of the accuracy of tumor segmentation in PET images. A special focus of my efforts is the development of a method for Quantitative Autoradiography of Biopsy Specimens (QABS), which allows in-situ validation of new radiopharmaceuticals with high spatial resolution, provides additional reference data for pathology-PET/CT image data sets, and has the potential to offer useful information for guiding interventional radiology procedures and localized cancer therapies.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Assen S. Kirov discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures